Hepatitis/MASH

Glecaprevir and pibrentasvir (Mavyret) shows efficacy across hepatitis C genotypes.

Direct-acting antivirals drugs show similar cure rates in co-infected patients as high as mono-infected patients.

Significant gains have been made against viral hepatitis.

Top news of the day from across the healthcare landscape.

Top news of the day from across the healthcare landscape.

Nine other countries are on track to eliminate the hepatitis C virus by 2030.

Officials with the FDA have approved an adjuvanted hepatitis B vaccine, recombinant [Heplisav-B, Dynavax] for the prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older.

Top news of the week from Specialty Pharmacy Times.

Heplisav-B is the only 2-dose hepatitis B vaccine recombinant approved in the United States.

Patients without cirrhosis who achieved a sustained virological response had the lowest risk of hepatocellular carcinoma linked to hepatitis C virus.

Top news of the day from across the healthcare landscape.

Top news of the day from across the healthcare landscape.

Patients with hepatitis C who achieved sustained virologic response with a direct-acting antiviral maintained health improvements that enhanced their long-term quality of life.

Low incidence of 14-3-3η in patients with long-term RA, chronic HCV with arthralgias.

An aspirin a day may reduce their risk of hepatocellular carcinoma in patients with hepatitis B virus.

Many new antiviral drugs that treat hepatitis C have similar efficacy, but come with different advantages and disadvantages.

Top news of the day from across the healthcare landscape.

Top news of the day from across the healthcare landscape.

Hepatitis B virus is known to increase the risk of cirrhosis and hepatocellular carcinoma.

A hepatitis C virus diagnosis may curb drug use among those in treatment.

This year, the FDA is on pace to approve about 38 new medications. Here is a look at 4 of those.

Veterans may be up to 5 times more likely to have hepatitis C than the general population.

Top news of the day from across the healthcare landscape.

Top news of the day from across the healthcare landscape.

Patients with hepatitis C virus achieve treatment success with specialists, primary care physicians, and nurse practitioners.

The lack of association of SVR with ribavirin dose reflects the wide variance in plasma levels between individuals with hepatitis C receiving the same weight-based dosage.

Heart transplant patients with hepatitis C often cannot not tolerate interferon-based regimens due to cardiac toxicity and other heart-related problems.

Drinking coffee may have more profound survival benefits for patients with HIV and hepatitis C than for the general population.

Researchers continue to focus on developing an 8-week treatment regimen for hepatitis C virus.